<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620707</url>
  </required_header>
  <id_info>
    <org_study_id>RGS@Home2020</org_study_id>
    <nct_id>NCT04620707</nct_id>
  </id_info>
  <brief_title>RGS@Home: Personalized 24/7 Home Care Post-stroke</brief_title>
  <official_title>RGS@Home Project: Scaling ICT Based Neurorehabilitation to Personalized 24/7 Home Care Post-stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Bioengineering of Catalonia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for Bioengineering of Catalonia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke represents one of the main causes of adult disability and will be one of the main&#xD;
      contributors to the burden of disease in 2030. However, the investigator's healthcare systems&#xD;
      do not have enough resources to cover the current demand let alone its future increase. There&#xD;
      is a need to deploy new approaches that advance the current rehabilitation methods and&#xD;
      enhance their efficiency.&#xD;
&#xD;
      One of the latest approaches used for the rehabilitation of a wide range of deficits of the&#xD;
      nervous system is based on virtual reality (VR) applications, which combine training&#xD;
      scenarios with dedicated interface devices. Market drivers exist for new ICT based treatment&#xD;
      solutions. IBEC/ Eodyne Systems has developed and commercialised the Rehabilitation Gaming&#xD;
      System (RGS), a science-based ICT solution for neurorehabilitation combining brain theory,&#xD;
      AI, cloud computing and virtual reality and targeting motor and cognitive recovery after&#xD;
      stroke. RGS provides a continuum of evaluations and therapeutic solutions that accompany the&#xD;
      patient from the clinic to the therapy centre. RGS has been clinically validated showing its&#xD;
      superiority over other products while reducing cost also through its use of standard&#xD;
      off-the-shelf hardware and a Software as a Service model (SaaS). Commercial evaluations have&#xD;
      shown that RGS acts as a workforce multiplier while delivering a high quality of care at&#xD;
      clinical centres (RGS@Clinic). However, in order to achieve significant benefits in the&#xD;
      patients' QoL, it is essential that RGS becomes an at home solution providing 24/7 monitoring&#xD;
      and care. For this reason, this project aims at investigating the RGS acceptability and&#xD;
      adoption model.&#xD;
&#xD;
      The findings derived from this study will contribute to establish a novel and superior&#xD;
      neurorehabilitation paradigm that can accelerate the recovery of hemiparetic stroke patients.&#xD;
      Besides the clinical impact, such achievement could have relevant socioeconomic impact.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the score of the upper extremity section of the Fugl-Meyer Assessment Test [min=0, max=66]. Higher scores indicate better functioning.</measure>
    <time_frame>12 weeks.</time_frame>
    <description>Change in score from baseline to end of treatment (12 weeks).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Barthel Index [min=0, max=100]. Higher scores indicate better functioning.</measure>
    <time_frame>12 weeks.</time_frame>
    <description>Change in score from baseline to end of treatment (12 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Barthel Index [min=0, max=100]. Higher scores indicate better functioning.</measure>
    <time_frame>12 months.</time_frame>
    <description>Change in score from baseline to end of treatment (12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients that are readmitted into the hospital (inpatient) after being discharged to at-home status.</measure>
    <time_frame>12 months.</time_frame>
    <description>Number of patients from baseline to 12 months post-baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Stroke Specific Quality Of Life scale (SS-QOL) [min=49, max=245]. Higher scores indicate better functioning.</measure>
    <time_frame>12 weeks.</time_frame>
    <description>Change in score from baseline to end of treatment (12 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Stroke Specific Quality Of Life scale (SS-QOL) [min=49, max=245]. Higher scores indicate better functioning.</measure>
    <time_frame>12 months.</time_frame>
    <description>Change in score from baseline to follow-up (12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the SIS (Stroke impact Scale) [min=0, max=42]. Higher scores indicate better functioning.</measure>
    <time_frame>12 weeks.</time_frame>
    <description>Change in score from baseline to end of treatment (12 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the SIS (Stroke impact Scale) [min=0, max=42]. Higher scores indicate better functioning.</measure>
    <time_frame>12 months.</time_frame>
    <description>Change in score from baseline to follow-up (12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Hamilton Scale Depression [min=0, max=52]. Lower scores indicate less impairment.</measure>
    <time_frame>12 weeks.</time_frame>
    <description>Change in score from baseline to end of treatment (12 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Hamilton Scale Depression [min=0, max=52]. Lower scores indicate less impairment.</measure>
    <time_frame>12 months.</time_frame>
    <description>Change in score from baseline to follow-up (12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Visual Analogue Score (VAS) [min=0, max=10]. Lower scores indicate less impairment.</measure>
    <time_frame>12 weeks.</time_frame>
    <description>Change in score from baseline to end of treatment (12 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Ashworth Scale [min=0, max=4]. Lower scores indicate less impairment.</measure>
    <time_frame>12 months.</time_frame>
    <description>Change in score from baseline to follow-up (12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Fatigue Severity Scale [min=9, max=63]. Higher scores indicate more fatigue.</measure>
    <time_frame>12 weeks.</time_frame>
    <description>Change in score from baseline to end of treatment (12 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Fatigue Severity Scale [min=9, max=63]. Higher scores indicate more fatigue.</measure>
    <time_frame>12 months.</time_frame>
    <description>Change in score from baseline to follow-up (12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Wellbeing questionnaire (SF-36) [min=0, max=100]. Higher scores indicate more wellbeing.</measure>
    <time_frame>12 weeks.</time_frame>
    <description>Change in score from baseline to end of treatment (12 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Wellbeing questionnaire (SF-36) [min=0, max=100]. Higher scores indicate more wellbeing.</measure>
    <time_frame>12 months.</time_frame>
    <description>Change in score from baseline to follow-up (12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the score of the upper extremity section of the Fugl-Meyer Assessment Test. [min=0, max=66]. Higher scores indicate better functioning.</measure>
    <time_frame>12 months.</time_frame>
    <description>Change in score from baseline to follow-up (12 months).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of falls reported by the participants.</measure>
    <time_frame>12 weeks.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of falls reported by the participants.</measure>
    <time_frame>12 months.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in Barthel Index [min=0, max=100]. Higher scores indicate better functioning.</measure>
    <time_frame>6 months.</time_frame>
    <description>Change in score from baseline to follow-up (6 months).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the stroke specific Quality of Life scale (SS-QOL) [min=49, max=245]. Higher scores indicate better functioning.</measure>
    <time_frame>6 months.</time_frame>
    <description>Change in score from baseline to follow-up (6 months).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the Wellbeing questionnaire (SF-36) [min=0, max=100]. Higher scores indicate more wellbeing.</measure>
    <time_frame>6 months.</time_frame>
    <description>Change in score from baseline to follow-up (6 months).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the score of the upper extremity section of the Fugl-Meyer Assessment Test [min=0, max=66]. Higher scores indicate better functioning.</measure>
    <time_frame>6 months.</time_frame>
    <description>Change in score from baseline to follow-up (6 months).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hemiparesis;Poststroke/CVA</condition>
  <condition>Stroke, Acute</condition>
  <condition>Motor Disorders</condition>
  <condition>Spasticity, Muscle</condition>
  <arm_group>
    <arm_group_label>RGS based therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment as usual</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RGS based training and monitoring</intervention_name>
    <description>The RGS treatment will consist in a variable number of sessions per week of RGS-based training. Each session consists of cognitive and motor training involving reaching, grasping, placing virtual objects. The duration of the training period will be variable. Patients will use the RGS@Clinic from admission to discharge, and will have the RGS@Home during the first 3 months of the outpatient stage after recruitment. After this period of time, the patient will be evaluated by clinicians and the RGS@Home system will be collected. The RGS-Wear will be kept by the patient also during the follow-up period, up to 1 year post-recruitment.</description>
    <arm_group_label>RGS based therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Therapy as usual</intervention_name>
    <description>The patients will follow treatment as usual, including conventional rehabilitation and physical therapy when corresponding. The exact treatment that the patients will receive will depend on the local medical guidelines.</description>
    <arm_group_label>Treatment as usual</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients presenting a first-ever ischemic or intracerebral hemorrhagic stroke.&#xD;
&#xD;
          -  A CT SCAN and/or MRI had exclude other pathologies.&#xD;
&#xD;
          -  Lesion localization by clinical symptoms/signs.&#xD;
&#xD;
          -  Moderate to mild proximal upper limb motor impairment (MRCâ‰¥2).&#xD;
&#xD;
          -  Age 20-85 years old.&#xD;
&#xD;
          -  Able to sit on a chair or a wheelchair interacting with the RGS during a full session,&#xD;
             and be capable and willing to participate in RGS therapy.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Presence of a condition or abnormality that in the opinion of the investigator would&#xD;
             compromise the safety of the patient or the quality of the data.&#xD;
&#xD;
          -  Severe cognitive capabilities that prevent the execution of the experiment (MoCA &lt;&#xD;
             19). This cut-off score is based on pilot study (Maier, M. et al, 2019).&#xD;
&#xD;
          -  Arteriovenous malformation or lesions not related with a stroke.&#xD;
&#xD;
          -  Severe associated impairment such as spasticity, communication disabilities&#xD;
             (sensorial, Wernicke aphasia or apraxia), major pain or other neuromuscular&#xD;
             impairments or orthopedic devices that would interfere with the correct execution of&#xD;
             the experiment (Modified Ashworth Scale &lt; 3).&#xD;
&#xD;
          -  Unable to use the RGS independently according to the therapist's observations and&#xD;
             lacking support from a caregiver to use the RGS.&#xD;
&#xD;
          -  Refusal to sign the consent form.&#xD;
&#xD;
          -  Pre-stroke history of upper limb motor disability.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paul Verschure, PhD</last_name>
    <phone>+34934011918</phone>
    <email>paul.verschure@specs-lab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute for Bioengineering of Catalonia - Specs Lab</name>
      <address>
        <city>Barcelona</city>
        <zip>08930</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Verschure</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Paresis</mesh_term>
    <mesh_term>Motor Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

